Fusen Pharmaceutical Company Limited

SEHK:1652 Stok Raporu

Piyasa değeri: HK$702.3m

Fusen Pharmaceutical Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Fusen Pharmaceutical's earnings have been declining at an average annual rate of -63.6%, while the Pharmaceuticals industry saw earnings growing at 5.7% annually. Revenues have been growing at an average rate of 5.7% per year.

Anahtar bilgiler

-63.6%

Kazanç büyüme oranı

-63.6%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi5.6%
Gelir büyüme oranı5.7%
Özkaynak getirisi-17.3%
Net Marj-21.1%
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

May 21
Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

Fusen Pharmaceutical Company Limited's (HKG:1652) Popularity With Investors Under Threat As Stock Sinks 27%

Mar 31
Fusen Pharmaceutical Company Limited's (HKG:1652) Popularity With Investors Under Threat As Stock Sinks 27%

Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

Dec 14
Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

Here's Why Fusen Pharmaceutical (HKG:1652) Can Manage Its Debt Responsibly

Sep 02
Here's Why Fusen Pharmaceutical (HKG:1652) Can Manage Its Debt Responsibly

Fusen Pharmaceutical (HKG:1652) Seems To Use Debt Quite Sensibly

Apr 02
Fusen Pharmaceutical (HKG:1652) Seems To Use Debt Quite Sensibly

A Look At Fusen Pharmaceutical's (HKG:1652) Share Price Returns

Mar 06
A Look At Fusen Pharmaceutical's (HKG:1652) Share Price Returns

We Wouldn't Rely On Fusen Pharmaceutical's (HKG:1652) Statutory Earnings As A Guide

Feb 08
We Wouldn't Rely On Fusen Pharmaceutical's (HKG:1652) Statutory Earnings As A Guide

Is Fusen Pharmaceutical Company Limited's (HKG:1652) Recent Price Movement Underpinned By Its Weak Fundamentals?

Jan 18
Is Fusen Pharmaceutical Company Limited's (HKG:1652) Recent Price Movement Underpinned By Its Weak Fundamentals?

Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet?

Dec 28
Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet?

What You Need To Know About Fusen Pharmaceutical Company Limited's (HKG:1652) Investor Composition

Dec 07
What You Need To Know About Fusen Pharmaceutical Company Limited's (HKG:1652) Investor Composition

If You Had Bought Fusen Pharmaceutical (HKG:1652) Shares A Year Ago You'd Have Earned 34% Returns

Nov 20
If You Had Bought Fusen Pharmaceutical (HKG:1652) Shares A Year Ago You'd Have Earned 34% Returns

Gelir ve Gider Dağılımı

Fusen Pharmaceutical nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

SEHK:1652 Gelir, gider ve kazançlar (CNY Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 24425-9018898
31 Mar 24496-6320182
31 Dec 23566-3621465
30 Sep 23614-2422740
30 Jun 23663-1121639
31 Mar 23577-2319527
31 Dec 22492-3517315
30 Sep 22414-341608
30 Jun 22337-341460
31 Mar 22361-91510
31 Dec 21386171560
30 Sep 21420481600
30 Jun 21454791650
31 Mar 21470751750
31 Dec 20487701860
30 Sep 20473671900
30 Jun 20458651930
31 Mar 20433591820
31 Dec 19407531720
30 Sep 19397631540
30 Jun 19387721370
31 Mar 19424871380
31 Dec 184621021390
30 Sep 185071021580
30 Jun 18493981560
31 Mar 18473981460
31 Dec 17453971360
30 Sep 17427861270
31 Dec 16442951120
31 Dec 1536945860

Kaliteli Kazançlar: 1652 is currently unprofitable.

Büyüyen Kar Marjı: 1652 is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 1652 is unprofitable, and losses have increased over the past 5 years at a rate of 63.6% per year.

Büyüme Hızlandırma: Unable to compare 1652's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: 1652 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.4%).


Özkaynak Getirisi

Yüksek ROE: 1652 has a negative Return on Equity (-17.28%), as it is currently unprofitable.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin